Cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and the exposure of particular phagocytosis signaling molecules on the cell surface are just a few of the distinctive morphological and biochemical features of the cell death process known as apoptosis. Apoptosis-initiated cell death is distinct from necrosis-induced cell death. Apoptotic death, in contrast, is silent and orderly. Necrotic cells are typically recognized as a danger signal by the immune system, which causes inflammation.
There are two main methods for inducing apoptotic cell death: The intrinsic pathway, also known as the Bcl-2-regulated or mitochondrial pathway, is strictly regulated by the BCL-2 family of proteins and is activated by a variety of developmental cues or cytotoxic insults, such as viral infection, DNA damage, and growth-factor deprivation.The tumor necrosis factor (TNF) receptor family members, such as Fas or TNF receptor-1 (TNFR1), which contain an intracellular death domain and can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface, are what initiate the extrinsic or death-receptor pathway. Without the involvement of the BCL-2 family, this recruitment results in the subsequent activation of downstream (effector) caspases like caspase-3, -6, or -7.
Numerous human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome), may be influenced by changes in cell survival, according to studies. Some of these diseases may not progress naturally unless specific therapies that change the apoptotic threshold are used.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V35224 | Tandutinib hydrochloride (MLN518 hydrochloride; CT53518 hydrochloride) | 2438900-70-8 | Tandutinib HCl (MLN518 HCl) is a potent and specific inhibitor of FLT3 with IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50 of 0.17 μM and 0.20 μM, respectively. |
|
V54999 | Tanfanercept (HL036337; HBM9036) | 2119738-70-2 | Tanfanercept (HL036337) is an anti-TNF-α monoclonal antibody (mAb). |
|
V81519 | TAT-BH4 (Bcl-xL) | TAT-BH4 (Bcl-xL) is mainly localized in mitochondria and prevents apoptosis. | |
|
V81520 | TAT-BH4 (Bcl-xL) (TFA) | TAT-BH4 (Bcl-xL) TFA is mainly localized in mitochondria and can prevent apoptosis. | |
|
V35221 | TAT-GluN2BCTM | 1587742-50-4 | TAT-GluN2BCTM is a membrane-permeable (penetrable) DAPK1 targeting peptide. |
|
V81526 | TAT-NEP1-40 | TAT-NEP1-40 is a bioactive peptide that penetrates the brain barrier. | |
|
V78779 | TAT-NEP1-40 acetate | TAT-NEP1-40 acetate is a candidate for axonal regeneration and functional recovery after stroke. | |
|
V78778 | TAT-NEP1-40 TFA | TAT-NEP1-40 TFA are brain barrier-penetrating peptides. | |
|
V30327 | Taurochenodeoxycholic acid | 516-35-8 | Taurochenodeoxycholic acid (also called 12-Deoxycholyltaurine) is a bile salt produced in the liver of animals. |
|
V38710 | Taurochenodeoxycholic acid sodium salt | 6009-98-9 | Taurochenodeoxycholic acid sodium, thesodium salt ofTaurochenodeoxycholic acid, is a naturally occuring bile salt produced in the liver of animals/humans used as a detergent for the solubilization of lipids and membrane-bound proteins. |
|
V52593 | Taurochenodeoxycholic acid-d4 sodium (12-Deoxycholyltaurine-d4 (sodium)) | 2410279-85-3 | Taurochenodeoxycholic acid-d4 (sodium) is the deuterated form of Taurochenodeoxycholic acid. |
|
V56413 | Taurochenodeoxycholic acid-d9 sodium (12-Deoxycholyltaurine-d9 sodium) | 2483832-00-2 | Taurochenodeoxycholic acid-d9 (sodium) is the deuterated form of Taurochenodeoxycholic acid sodium. |
|
V52592 | Tauroursodeoxycholate-d4 sodium (Tauroursodeoxycholate-d4 (sodium); TUDCA-d4 (sodium); UR 906-d4 (sodium)) | 2410279-95-5 | Tauroursodeoxycholate-d4 (sodium) is the deuterated form of Tauroursodeoxycholate sodium. |
|
V56411 | Tauroursodeoxycholate-d5 (tauroursodeoxycholate d5) | 1207294-25-4 | Tauroursodeoxycholate-d5 is the deuterated form of Taouroursodeoxycholate. |
|
V55003 | Taxamairin B | 110300-77-1 | Taxamairin B is a potent anti-inflammatory agent. |
|
V35216 | TC11 | 100823-03-8 | TC11 is an MCL1 degrader and activator of Caspase-9 and CDK1. |
|
V35214 | TCS PrP Inhibitor 13 | 34320-83-7 | TCS PrP Inhibitor 13, as an anti-prion compound, is a cellular prion protein (PrPC) inhibitor. |
|
V41891 | TD-52 | 1798328-24-1 | TD-52, Erlotinib analog; protein phosphatase 2A (CIP2A) inhibitor |
|
V35213 | Tebentafusp (IMCgp100) | 1874157-95-5 | Tebentafusp (IMCgp100) is a bispecific fusion protein targeting gp100, a melanoma-associated antigen. |
|
V52670 | Tebufenozide-d9 (tebufenozide-d9) | 2469006-89-9 | Tebufenozide-d9 is the deuterated form of Tebufenozide. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
